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Two recent papers in Nature, Ben-Zvi et al. (2014) and Nguyen et al. (2014), report a surprising dual role for
the blood-brain barrier transporter MFSD2A in both establishing BBB integrity and in uptake of the fatty
acid DHA.Blood vessels in the brain are organized
with surprising precision, patterned in
parallel with the major brain circuits
tasked with sensation, memory, and
motion. The term ‘‘neurovascular unit’’
(NVU) has been coined to reflect this
intimate connection between neuronal
circuits and their associated blood
vessels (Moskowitz et al., 2010; Zlokovic,
2011; Iadecola, 2013). This tight inter-
relationship may reflect key functional
roles of blood vessels in neuronal normal
function and disease.
The CNS vascular system is a highly
dynamic multicellular structure capable
of integrating and responding to both
systemic and neural cues. At the core of
its proper functionality is the intimately
connected and highly coordinated NVU.
The NVU comprises vascular cells such
as endothelial cells and pericytes at the
capillary level and vascular smooth
muscle cells at the arterial level, glia
(e.g., astrocytes, microglia, oligoden-
drocytes), and neurons (Figure 1, top).
Proper signal transduction between these
different, but equally important, cell types
is essential for effective CNS functioning
underlying cortical and subcortical infor-
mation processing of motor functions as
well as the higher integrative CNS func-
tions associated with cognition, memory,
and learning. Prior studies using geneti-
cally manipulated mouse lines have
shown that disrupted crosstalk between
endothelial cells and pericytes (Armulik
et al., 2010; Daneman et al., 2010; Bell
et al., 2010) or astrocytes and pericytes
(Bell et al., 2012) leads to a loss of
cerebrovascular integrity. This in turn
leads to accumulation of neurotoxic
blood-derived products in the CNS
including hemoglobin, iron, thrombin,
fibrin, or plasmin resulting in oxidative728 Neuron 82, May 21, 2014 ª2014 Elsevierstress, intraneuronal accumulation of
toxic proteins, and/or neuronal detach-
ment from the extracellular matrix,
respectively, causing neuronal dysfunc-
tion, injury, neurodegeneration, and
neuronal loss (Bell et al., 2012; Winkler
et al., 2014).
In the NVU, the endothelial cells form a
continuous, highly specialized biological
membrane around blood vessels under-
lying the blood-brain barrier (BBB), which
limits the entry of plasma components,
red blood cells, and leukocytes into the
brain. Importantly, the BBB also regulates
the delivery of energy metabolites and
essential nutrients to the brain and main-
tains the removal from the brain to blood
of neurotoxic molecules. This transport
function of the BBB is controlled by highly
specialized substrate-specific transport
proteins expressed in brain endothelium,
such as, for example, (1) the glucose
transporter-1 (GLUT1) that directs influx
of glucose across the BBB, providing a
key energy substrate for neuronal meta-
bolism; (2) the monocarboxylate trans-
porter that mediates transport of lactate
and other monocarboxylates including
ketone bodies, as an alternative source
of brain energy; (3) multiple nutrient amino
acid transporters that maintain delivery of
all essential and nonessential amino acids
to neurons according to their respective
blood-to-brain interstitial fluid (ISF) con-
centration gradients; and/or (4) ABC
transporters that limit the penetration of
many drugs into the brain by an ‘‘up-hill’’
energy-dependent efflux (Zlokovic,
2008a).
The diffusion distances from the neigh-
boring capillaries to each neuronal cell
body within the CNS are extremely short,
i.e., 15–30 mm (Bell et al., 2010; Blinder
et al., 2013). These short diffusion path-Inc.ways allow rapid, almost instantaneous
(<1 s) delivery of glucose, other nutrients,
and/or small molecules to neurons as
soon as they cross the BBB and enter
the ISF. Most of these molecules and
nutrients also cross the blood-cerebro-
spinal fluid (CSF) barrier via specialized
transporters expressed in the choroid
plexus epithelium. However, the diffusion
of small polar molecules as well as large
molecules from CSF to neurons via CSF-
ISF diffusion pathway is several orders
of magnitude slower than the BBB
pathway. It would take hours or days for
small and large molecules, respectively,
to reach neurons from CSF because the
CSF-to-neuron diffusion distances are
several orders of magnitude greater than
from the BBB sites (Pardridge, 1991;
Zlokovic, 2011). Therefore, the BBB
endothelial transporters play a crucial
role in CNS health and disease both in
the adult and aging brain and during
CNS development.
In a recent paper in Nature, Ben-Zvi
et al. (2014) report that an orphaned
transporter, the major facilitator super
family domain containing 2a (Mfsd2a), is
selectively expressed in the BBB
endothelium and is required for normal
formation and maintenance of the BBB
integrity. Utilizing an improved method to
assess BBB integrity during mouse CNS
development, in which a small volume of
tracer is injected into embryonic liver to
minimize changes in blood pressure,
Ben-Zvi et al. (2014) show that the BBB
becomes functional at embryonic day
15.5 (E15.5). By comparing the
gene expression profiles of different
transcripts for transporters, transcription
factors, and secreted and transmembrane
proteins that are enriched in the BBB
endothelium (cortex) with the barrier
Figure 1. The Neurovascular Unit and Blood-Brain Barrier
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BBB (lung) endothelium, they
found that at embryonic day
E13.5 the levels of Mfsd2a
transcripts are higher by
80-fold in the BBB endothe-
lium.Utilizing in situ hybridiza-
tion and immunostaining,
they convincingly demon-
strate that Mfsd2a is ex-
pressed exclusively in brain
endothelium but is not ex-
pressed at detectable levels
in pericytes, astrocytes, or
neuronal cells, suggesting
that it has an endothelial cell-
specific role. Using trans-
genic Mfsd2a/ mice, Ben-
Zvi et al. (2014) show that
genetic deletion of Mfsd2a
leads to BBB defects in the
developing CNS, whereas
the patterning of vascular net-
works remains unaffected.
They also found that the BBB
breakdown in Mfsd2a/
mice is due to an uninhibited
bulk flow transcytosis across
the endothelium that is com-




To determine how their
findings in Mfsd2a/ mice
relate to previous findings
in pericyte-deficient mice
(Armulik et al., 2010; Bell
et al., 2010), Ben-Zvi et al.
(2014) reanalyzed the micro-
array data in Pdgfbret/ret
mice and found direct cor-
relation between the reduc-
tion of Mfsd2a gene ex-
pression and the degree of
pericyte coverage. Although
Mfsd2a/ mice had normal
pericyte coverage, they founda significant decrease in MFSD2A protein
in brain endothelial cells in pericyte-defi-
cient Pdgfbret/ret mice particularly in the
microvessels lacking pericyte coverage.
Therefore, Ben-Zvi et al. (2014) concluded
that an increased vesicular trafficking un-
derlying Mfsd2a-dependent BBB break-
down (Figure 1, middle) could be, at least
in part, regulated by pericytes as sug-
gested by their data in pericyte-deficientmice showing strong downregulation of
endothelial MFSD2A (Figure 1, bottom).
As downregulation of tight junction
proteins has also been demonstrated to
contribute to BBB breakdown in peri-
cyte-deficient mouse lines (Bell et al.,
2010), collectively these data indicate
that pericytes may regulate both
Mfsd2a-dependent andMfsd2a-indepen-
dent BBB breakdown by controlling theNeuron 82, May 21,levels of tight junction pro-
teins. Future studies are
needed, however, to identify
the signal transduction path-
ways and transcriptional
regulation between pericytes
and endothelial cells that
control Mfsd2a expression
and the associated Mfsd2a-
dependent changes in BBB
permeability, as well as
Mfsd2a-independent regula-
tion of the tight junction pro-
teins in the endothelium.
Moreover, it would be inter-
esting to find out whether
ablation of pericytes in adult-
hood can also lead to BBB
breakdown through downre-
gulation ofMfsd2a expression
and/or reductions in the tight
junction proteins as found in
models of inherited pericyte
deficiency.
Is MFSD2A a real orphan
transporter? The accompa-
nying paper in Nature by
Nguyen et al. (2014) was
focused on the transport
function of Mfsd2a, asking
whether MSFD2A has a role
in BBB influx of substrates
essential for normal neuronal
function. Besides confirming
exclusive MSFD2A expres-
sion in BBB endothelium
as they show in the young
adult mouse brain, Nguyen
et al. (2014) performed a
series of in vivo and in vitro
experiments and found that
MFSD2A is the major
transporter mediating brain
uptake of docosahexaenoic
acid (DHA), an omega-3 fatty
acid essential for normal brain
growth and cognitive function
(Figure 1, top). Using lipido-mic analysis, Nguyen et al. (2014) show
that Mfsd2a/ mice have significantly
reduced levels of DHA in brain accompa-
nied with neuronal cell loss in the
hippocampus and cerebellum, neurolog-
ical and behavioral deficits, and reduced
brain size (Figure 1 middle). Using
cell-based assays and brain uptake
studies in Mfsd2a/ mice, they next
show that Mfsd2a transports DHA and2014 ª2014 Elsevier Inc. 729
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BBB only in the form of esters with
lysophosphatidylcholines (LPCs), but not
as free unesterified fatty acids. They also
show that MSFD2A transport protein
prefers long-chain fatty acids such as
LPC-oleate and LPC-palmitate but does
not transport LPCs with less than a 14-
carbon acyl chain. Their study demon-
strates that LPC’s phosphor-zwitterionic
headgroup is critical for MFSD2A-medi-
ated transport and that Mfsd2a/ mice
have substantially reduced uptake of
labeled LPC-DHA and other LPCs from
plasma into the brain.
These two studies, one demonstrating
a transport role of MFSD2A mediating
BBB uptake of an essential omega-3 fatty
acid, and the other showing its critical role
in the formation of the BBB integrity,
raise several interesting questions. For
example, to what extent the neuronal
phenotype as seen by Nguyen et al.
(2014) in Mfsd2a/ mice is related to a
shortfall in DHA transport as suggested
by the authors, as opposed to nonmeta-
bolic neuronal injury and loss mediated
by unrestricted influx of potentially toxic
blood-derived products into the brain
across the defective BBB (Figure 1,
middle), as previously shown in other
models of a chronic BBB breakdown
including pericyte-deficient mice (Bell
et al., 2010), apolipoprotein E4-express-
ing mice (Bell et al., 2012), and/or after
experimentally induced BBB breakdown
in a mouse model of amyotrophic lateral
sclerosis (ALS) (Winkler et al., 2014).
It would be quite intriguing to find
out whether pericytes can regulate
MFSD2A-mediated DHA BBB transport
across brain endothelium as they regulate730 Neuron 82, May 21, 2014 ª2014 Elsevierthe BBB permeability, as suggested by
Ben-Zvi et al. (2014) (Figure 1, bottom).
Finally, in regards to significance of these
two new studies to the field of clinical
neurosciences, one can speculate that
the present findings might have even
broader implications for better under-
standing of neurological diseases associ-
ated with neurovascular dysfunction,
particularly the BBB breakdown and
pericyte degeneration and/or loss, as
seen in Alzheimer’s disease, ALS, and/or
after an ischemic CNS injury and stroke
(Zlokovic, 2008b, 2011; Moskowitz et al.,
2010; Carmeliet and Ruiz de Almodovar,
2013; Iadecola, 2013).
A discovery that a transport protein
can play a dual role at the BBB by regu-
lating brain uptake of an essential sub-
strate and by controlling at the same
time the BBB integrity is provocative
and important. Here, MFSD2A joins the
club of GLUT1 glucose transporter,
which has previously been demon-
strated to be essential for BBB formation
in the developing CNS in zebrafish
(Zheng et al., 2010) in addition to its
established role in regulating glucose
uptake by the brain. Whether MFSD2A
and GLUT1 are two exceptional trans-
port proteins that can play this dual
role at the BBB, or whether they are
only the first two transporters discov-
ered of a more common class of trans-
port proteins with a dual role at the
BBB, remains to be seen!
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